---
title: Cure-in’s Breast Biopsy Robot Puts Small Hospitals in the MRI Fast Lane
description: MR-SON automates MRI-guided breast biopsies, helping regional hospitals improve cancer diagnostics, reduce costs and expand local care delivery
author: Dr Marina Nani (Editor-in-Chief)
date: 2025-11-21T09:37:35.000Z
updated: 2026-02-26T18:01:38.761Z
canonical: https://www.sovereignmagazine.com/article/cure-in-s-breast-biopsy-robot-puts-small-hospitals-in-the-mri-fast-lane
image: https://cdn.nanimediahouse.com/66UApqohX2uVcgFI3HRt.jpg
categories: Science & Tech
content_type: Spotlight
region: Global
publication: Sovereign Magazine
---

When Claire receives the call that her routine breast MRI has found something suspicious, her local regional hospital delivers the familiar disappointment: she’ll need to travel two hours to the city for a biopsy. The overnight stay, the unfamiliar hospital, the extra costs, all because her perfectly capable local facility lacks the specialised staff needed for MRI-guided breast biopsies.

This scenario plays out thousands of times across regional hospitals worldwide. Whilst these facilities can perform the initial MRI screening that detects potential problems, they must send patients elsewhere for the crucial follow-up procedure that determines whether suspicious lesions are actually cancerous.

## The Staffing Bottleneck

Traditional MRI-guided breast biopsies require removing patients from the MRI machine whilst highly trained radiologists manually navigate needles to suspicious tissue. The process typically takes around one hour, demands considerable expertise and creates a staffing bottleneck that prevents many smaller hospitals from offering the service.

[According to radiological surveys](https://pubs.rsna.org/doi/full/10.1148/rg.210126), regional hospitals without in-house biopsy capability rely on referral partnerships with specialised centres, as recommended by the American College of Radiology accreditation process. This system works for patient safety but creates inconvenience and potential delays.

Now medical robotics company Cure-in believes its MR-SON system can change this. The MRI-compatible robot automates needle positioning for breast biopsies, potentially allowing hospitals without specialised teams to perform these procedures locally.

## What MR-SON Actually Does

Cure-in’s MR-SON (MRI-guided Semi-Automated Needle Biopsy Robot System) represents over a decade of development that began in 2011 at South Korea’s National Cancer Center. The system combines an MR-compatible biopsy robot with image-guided navigation technology.

The key difference lies in automation. Rather than requiring manual needle navigation by specialists, MR-SON uses automated guidance to position MR-safe needles without repositioning patients. This reduces procedure time to just over 30 minutes – more than halving the typical hour-long manual process.

The robot features a slim design that approaches from the side without altering existing breast coil structures, allowing integration into current MRI setups. Cure-in claims this automation reduces both procedure time and the need for highly specialised staff.

## The Business Problem for Regional Hospitals

The inability to perform MRI-guided biopsies creates both financial and operational challenges for regional hospitals. [Research shows rural and regional hospitals face substantial revenue loss](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247687/) when referring patients for advanced breast cancer diagnostics, as they don’t receive reimbursement for expensive procedures performed elsewhere despite their initial clinical investments.

With breast biopsy procedures costing between $520 and $1,216 depending on anaesthesia requirements, the referral system means regional hospitals lose both the procedure revenue and often the ongoing patient relationship. Meanwhile, patients face travel costs, overnight stays and treatment delays.

Regional hospitals already struggle with [complex vendor relationships and equipment management challenges](https://www.sovereignmagazine.com/article/why-hospitals-are-tired-of-juggling-vendors-and-what-one-solution-equipment-platforms-mean-fo) that affect their ability to offer comprehensive services. Adding specialised biopsy capabilities requires significant staffing and training investments that many cannot justify.

In the United States, where Cure-in has identified its primary target market, this referral pattern is particularly pronounced. The country sees approximately 310,000 new breast cancer cases annually, with roughly 10-15% of all biopsy candidates requiring MRI-guided follow-up procedures.

## Cure-in’s Market Strategy

Cure-in’s approach acknowledges this market reality. Initially targeting large cancer centres with high patient volumes, the company plans to expand to mid-sized hospitals equipped with MRI once clinical stability is confirmed.

‘Hospitals can retain patients, and patients can avoid long-distance travel and overnight stays,’ the company states, highlighting the dual benefit of keeping revenue local whilst improving patient convenience.

Samuel Byeongjun Park, Cure-in’s co-CEO, recently relocated the company to Pangyo to enhance investor and partner relationships. ‘Pangyo provides an optimal environment for meeting investors and partners and expanding our network,’ Park explains.

## Market Competition and Validation

Cure-in enters a [breast biopsy devices market valued at approximately $2.65 billion](https://www.credenceresearch.com/industry/biopsy-devices-market) in 2022, growing at above 5.8% annually. The sector increasingly emphasises automation and MRI integration.

Competitors include [Insight Medbotics with its IGAR system](https://www.marketsandmarkets.com/Market-Reports/biopsy-device-market-132886515.html) – the first FDA 510(k)-cleared MRI-compatible robotic breast biopsy device. Hologic, Abbott and Medtronic also offer advanced imaging-guided systems, though most focus on larger hospital markets.

Medical device automation is gaining traction across specialties, with [AI-powered cardiac mapping systems](https://www.sovereignmagazine.com/article/ai-powered-cardiac-mapping-solutions-herald-new-era-in-heart-disease-treatment) demonstrating similar approaches to reducing specialist dependency whilst improving precision.

## Regulatory and Adoption Hurdles

Cure-in faces the typical pathway for MRI-compatible medical devices: [FDA 510(k) clearance requiring substantial equivalence](https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k) to existing devices and compliance with [FDA MRI safety standards](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/testing-and-labeling-medical-devices-safety-magnetic-resonance-mr-environment).

The company aims to begin pivotal clinical trials by end of 2025, complete them in the first half of 2026 and obtain regulatory approval in the second half, enabling sales to commence. European entry will follow, starting with Germany given its large breast cancer patient population and high MRI adoption.

Beyond regulatory approval, Cure-in must establish distribution networks and maintenance capabilities across target markets. The company seeks investment partners to build local subsidiaries and commercialisation infrastructure in the US and Europe.

## Can Automation Drive Adoption?

Healthcare automation faces adoption challenges even when the technology works. [Administrative automation in healthcare](https://www.sovereignmagazine.com/article/the-billion-dollar-phone-problem-the-hard-numbers-behind-ai-agents) shows similar patterns where cost savings and efficiency gains must overcome institutional inertia and training requirements.

Mid-sized hospitals that represent MR-SON’s main target market must weigh equipment costs against the revenue potential of keeping breast biopsy patients local. These facilities need to consider more than just procedure economics – patient satisfaction, competitive positioning and the value of offering comprehensive breast cancer care without referrals all factor into the decision.

The success of robotic breast biopsy systems will depend on regulatory approval, cost structures that work for mid-sized hospitals and clinical outcomes that match promises of reduced procedure times and simplified workflows. Whether automation can bring advanced breast cancer diagnostics to patients outside major medical hubs remains to be proven in practice.